Kornimate/medical-research-clean huggingface dataset:
a study of pet scans with the radioactive tracer 18f-bms-986229 in patients with esophageal, stomach, or gastroesophageal junction cancer

Conditions: Esophagogastric Cancer; Esophagus Cancer; Esophageal Cancer; Gastric Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Gastroesophageal Junction Squamous Cell Carcinoma

Summary: the purpose of the study is to test 18f-bms-986229 positron emission tomography (pet) imaging a practical and safe way to check the status of esophageal, stomach, and gastroesophageal junction cancer.


Eligibility criteria:
inclusion criteria: * participant must have pathologically or cytolofically confirmed (at msk) esophageal, gastric, or gastroesophageal junction adenocarcinoma or squamous cell carcinoma * pd-l1-positive expression in \>/=1% of the tumor or stromal cells. pd-l1 expression will be reviewed by msk pathologist, scored and recorded using the combined positive score (cps) formula (number of pd-l1 positive tumor cells, lymphocytes, and macrophages divided by the number of tumor cells x 100). * participants must have disease that can be evaluated radiographically. this may be measurable disease or nonmeasurable disease according to recist 1.1. * concurrent therapy is allowed. * age 18 years or older. * eastern cooperative oncology group (ecog) performance status 0-2. * female subjects of childbearing potential must have a negative urine or serum pregnancy test within 24 hours before receiving the first dose of the study medication. if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. * adequate organ function, as defined in table 1. all screening labs should be performed within 14 days of initiation of treatment. hematological absolute neutrophil count: \>/=1,000/mcl platelets: \>/=90,000/mcl hemoglobin: \>/=8 g/dl renal serum creatinine: \</=2.0 x upper limit of normal (uln) hepatic serum total bilirubin: \</=2.5 x uln (1.5 mg/dl or 25.65 umol/l) or (except patients with gilbert's disease \[\</=3 x uln\]) ast (sgot) and alt (sgpt): \</=2.5 x uln or \</=5 x uln for subjects with liver metastases exclusion criteria: * known diagnosis of immunodeficiency or receipt of systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of trial treatment * history of active tuberculosis (bacillus tuberculosis) * active or documented autoimmune or inflammatory disorder (including inflammatory bowel disease, systemic lupus erythematous, wegener syndrome \[granulomatosis with polyangitis\], myasthenia gravis, graves' disease, rheumatoid arthritis, hypophysitis, uveitis) within the 3 years before the start of treatment. the following are exceptions to this criterion: * subjects with vitiligo or alopecia * subjects with hypothyroidism (e.g., following hashimoto syndrome) who are stable with hormone replacement therapy or with psoriasis not requiring systemic treatment

Keywords: 18f-bms-986229 memorial sloan kettering cancer center 19-122
profile of depressive symptoms in parkinsons disease

Conditions: Parkinson Disease; Depression

Summary: to explore or establish the relationship between cognitive, mood and motor symptoms in pd to scores on depression rating scales in a naturalistic setting.


Eligibility criteria:
inclusion_criteria: observation criteria: * are able to provide written informed consent in accordance with good clinical practice (gcp) and local legislation * have idiopathic parkinsons disease according to the united kingdom parkinsons disease society brain bank diagnostic criteria for parkinsons disease * show no impairment of cognitive function (mmse score ?24) * are with or without symptoms of depression (full range) * are stable on anti-parkinson/anti-depressive treatment for at least 1 month before entering the study * are or are not on concomitant antidepressant treatment * are in the on state during the observation period * did not previously undergo pd surgery
serotonin/dopamine antagonism of cocaine effect: 2 - 2

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate use of risperidone with cocaine abusers. study measures incorporate an appropriate integration of behavioral and neurobiological indices.

risperidone in low doses is compared with placebo in a 6-week randomized trial. subjects also receive supportive counseling. outcome measure include rating of behavior, mood, drug abuse, global function, and urine toxicology.

Eligibility criteria:
inclusion criteria: cocaine abuse or dependence exclusion criteria: dependence on other drugs. major psychiatric illness

Keywords: cocaine dependence
effects of blueberries in older adults

Conditions: Blood Pressure; Orthostatic Hypotension; Vascular Diseases

Summary: this randomized, parallel-design trial will evaluate specific clinical and physiological effects of whole blueberries in adults 70 years of age or older.

although much is already known about the benefits of a healthy diet for the prevention of a wide range of chronic diseases, including the particular health benefits of anthocyanin-rich foods, these effects have been examined with much less frequency in older adults, who tend to be excluded from formal feeding studies and, until recently, have represented a small proportion of ongoing cohort studies. the proposed study will randomize approximately 46 women and 24 men, representative of the proportion of elderly women and men in the u.s. to consume either: 1. 1 cup of frozen blueberries daily for 12 weeks or 2. 2-3 dried dates daily for 12 weeks. dates were chosen as a control food because they contain negligible polyphenols, proportionately high caloric content, and a convenient form for storage. after the 12-week intervention, researchers will repeat in-person study assessments from baseline.

Eligibility criteria:
inclusion criteria: * 70 years old * independent-living exclusion criteria: * cardiovascular event or procedure within 3 months of randomization * aha class iii-iv heart failure * intolerance or allergy to blueberries or dates * history of gastric bypass surgery * any planned hospitalization or vacation in the ensuing 4 months * any current cancer treatment * end-stage renal disease * any organ transplant * uncontrolled diabetes mellitus with hemoglobin a1c \>9% * systolic blood pressure \>200 mmhg * inability to provide personal informed consent (e.g. cognitive impairment) * investigator concern

Keywords: blueberries dates older adults blood pressure fruit vascular health dietitian
rehabilitation following laparoscopic colonic surgery

Conditions: Colonic Cancer; Postoperative Care; Fatigue

Summary: the standard procedure for treating colonic cancer is changing from open surgery to laparoscopic surgery. following open colonic surgery patients are fatigued and loss body mass and have a reduction in physical function, but the investigators do not know if this is also the case following laparoscopic surgery. this study examines how fatigue, quality of life, physical function, and body composition changes following laparoscopic colonic surgery. patients are examined preoperatively and postoperative day 10 and 30.


Eligibility criteria:
inclusion criteria: * elective colonic cancer surgery * hemicolectomy or sigmoid resection * informed consent exclusion criteria: * disseminated cancer * contraindications for laparoscopic surgery * dementia or serious psychiatric disease * diseases or other aspects that prohibit participation

Keywords: colonic surgery postoperative care fatigue physical function quality of life
analgesic response to opioids in patients with fibromyalgia after conventional acupuncture versus sham acupuncture

Conditions: Fibromyalgia

Summary: this study aims to see whether acupuncture can help fibromyalgia patients by giving them acupuncture treatment and seeing whether acupuncture helps enhance the effects of an opioid.

the investigator hypothesizes that traditional acupuncture (ta) enhances binding of the mor receptor which will then enhance the pain-reducing effects of opioids compared to sham acupuncture (sa). the investigator will test the hypothesis by giving participants a validated brief pain inventory to complete during the pre-therapy opioid challenge and one week after ta or sa therapy is completed.

Eligibility criteria:
inclusion criteria: * are 18 - 80 years old * have been diagnosed with fibromyalgia for more than 6 months * are already using chronic, continuous opioid therapy, including but not limited to the use of hydrocodone (norco), oxycodone (percocet), morphine, methadone or tylenol #3 daily * have moderate to excruciating pain at baseline, determined by a 5 or greater score on the visual analogue scale (vas) exclusion criteria: * are younger than 18 or older than 80 years old * have been diagnosed with a substance use disorder (sud) * pregnant * have an active litigation or worker's compensation case * have an active mental health diagnosis, such as bipolar disorder, psychosis, or suicidal ideation * are prescribed and actively using low dose naltrexone . have tried acupuncture in the last 6 months

Keywords: acupunture
efficacy and safety of methylene blue in the treatment of severe septic shock

Conditions: Septic Shock; Methylene Blue; Sepsis

Summary: the goal of this clinical trial is to investigate whether methylene blue injection can safely and effectively improve the survival rate of patients with severe septic shock, shorten the duration of norepinephrine use, reduce the dosage of vasopressors, promptly correct hemodynamics, and improve tissue perfusion and organ function impairment.

researchers will compare methylene blue to a placebo (a look-alike substance that contains no drug) to see if methylene blue works to treat severe septic shock. participants will: administer a loading dose of 2.5 mg/kg via micro-pump over 15 minutes, followed by a maintenance infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. if norepinephrine needs to be increased to 0.25 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed. primary study endpoint - 28-day all-cause mortality rate starting from the diagnosis of septic shock. secondary study endpoints * time from the start to the discontinuation of norepinephrine after the diagnosis of septic shock. * total dose of norepinephrine used (from enrollment to 72 hours). * number of days without norepinephrine within 28 days. * duration of mechanical ventilation. * rate of crrt (continuous renal replacement therapy). * length of icu stay. * total hospital stay. record the following indicators before methylene blue intervention and at 24 hours, 72 hours, and 5 days after the intervention: * highest serum lactate level. * lowest mean arterial pressure. * alanine aminotransferase (alt). * total bilirubin. * creatinine. * oxygenation index (p/f ratio). * creatine kinase-mb (ck-mb). * troponin i (tni). * systemic vascular resistance index (svri).

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. meets the sepsis 3.0 criteria for septic shock: patients with infection who, despite adequate fluid resuscitation, require vasopressor therapy to maintain a mean arterial pressure (map) of ≥ 65 mmhg and have a blood lactate concentration \> 2 mmol/l. 3. diagnosed with septic shock and started on norepinephrine within 24 hours. 4. requires a norepinephrine dose of ≥ 0.1 μg/kg/min to maintain a map of ≥ 65 mmhg. exclusion criteria: 1. pregnant or breastfeeding women. 2. individuals allergic to methylene blue or any components of the methylene blue injection. 3. individuals with a personal or family history of glucose-6-phosphate dehydrogenase (g6pd) deficiency. 4. patients with an expected survival time of less than 48 hours. 5. patients who have been on norepinephrine for more than 24 hours.

Keywords: septic shock methylene blue sepsis
assessment of a modified minimally invasive esophagectomy

Conditions: Esophageal Cancer

Summary: this is a retrospective case series of a novel fully minimally invasive esophagectomy procedure for patients with primary esophageal cancer.


Eligibility criteria:
inclusion criteria: * patient with primary esophageal cancer of any cell type * underwent the novel minimally invasive esophagectomy procedure at the kaiser permanente northern california oakland medical center by one of the study author-surgeons exclusion criteria: * non-elective procedure * less than 90 days of post-discharge follow-up
comparison of gait in different support conditions for foot drop

Conditions: Foot Drop, Unspecified Foot

Summary: foot drop is a complication accompanying a variety of conditions and refers to difficulty in lifting the foot upwards about the ankle. foot drop is a common outcome of conditions including cerebral palsy, brain/spinal cord injury, muscular dystrophy, stroke and after chemotherapy. foot drop can lead to trips and falls for the individual if the foot catches on the ground when walking, negatively impacting on independence and quality of life. approximately 46,720 children and adolescents in the uk have the above conditions and current treatment for individuals with foot drop include use of a lycra sock for those requiring low support and a rigid ankle foot orthosis (afo) for those requiring high support. the current problem is that all children and adolescents requiring more than low support of the lycra sock are fitted with an afo, which can lead to muscles becoming weak over time as the afo restricts almost all movement about the ankle. this study will assess the use of a new device, the orthoped splint, in young people aged 4 - 17 years old who have moderate foot drop. the orthoped splint has been developed to be used as a long-term device and aims to reduce loss of strength by allowing more ankle function than an afo. this study aims to assess the feasibility of recruiting children and adolescents with foot drop into a study, collecting information on their movement and how well they walk when wearing different support devices for foot drop. each person in the study will be measured when walking barefoot (no external support) and when wearing an afo, lycra sock and the orthoped splint. this feasibility study will inform the design, management, and delivery of a future larger randomised, controlled, non-inferiority trial.


Eligibility criteria:
inclusion criteria: * age 4 - 17 years old * diagnosed moderate unilateral or bilateral foot drop * able to walk independently * minimum of 5 degrees of ankle dorsiflexion with or without gravity (oxford scale 2-4, clarkson (2010)) exclusion criteria: * younger than 4 or older than 17 years old * severe foot drop that requires higher levels of support than elastic splint * unable to walk independently * visual impairment when corrected to not be able to see targets when walking * unable to understand and or cooperate with study protocol * health contraindications to exercise e.g. cardiac disease

Keywords: orthotic afo
evaluation of a new oral contrast agent for mr enterography in the assessment of crohn disease in the small bowel

Conditions: Crohn Disease

Summary: the purpose of this study is to assess the exam quality and accuracy of mr using a new oral contrast agent for the evaluation of crohn disease in the small bowel.

crohn disease is an inflammatory condition that involves the small bowel. patients usually undergo multiple imaging exams in the diagnosis and surveillance of the disease. ct has been shown to have excellent results for detecting active inflammation. in the united states mr has lagged behind ct in utilization for imaging the small bowel. an advantage of mr over ct is the lack of radiation exposure to the patient. a new oral contrast agent is available that provides good distension of the small bowel and allows improved identification of active inflammation. the purpose of this study is to compare the accuracy of mr to ct using this new oral contrast agent and to assess exam quality.

Eligibility criteria:
inclusion criteria: * known or suspected crohn disease * undergoing colonoscopy and ct enterography exclusion criteria: * contraindication to mr

Keywords: crohn disease inflammatory bowel disease
effects of transcutaneous electrical nerve stimulation on cognitive function and upper limb motor function in people with chronic stroke

Conditions: Chronic Stroke

Summary: upper limb impairment is present in more than 85% of people with stroke, which greatly affect the quality of life, social participation, and performance of daily activities of people with stroke. previous study also revealed that 53.4% of people after stroke experienced cognitive impairment. different cognitive domains might be affected following stroke, such as attention, memory, language, and orientation, and the problems with memory are often prominent. yet, there is no effective treatment for the post-stroke cognitive impairment. transcutaneous electrical nerve stimulation (tens) applied on thoracic region and transcutaneous vagus nerve stimulation (tvns) are simple and non-invasive treatment to improve upper limb motor function and cognitive function. however, no existing studies have explored on the effects of tens and tvns on cognitive function in people with stroke. therefore, the purpose of this study is to evaluate the effectiveness of tens on improving upper limb function and cognitive function in people with chronic stroke. also, this study will investigate the cortical response of people with stroke during tens by using eeg power spectrum analysis.

this study aims to investigate the effects of three intervention protocols in people with stroke. the participants in group a will receive tens on c6 and t5 level of the spine with upper limb exercises. the participants in group b will receive tvns on the cymba conchae of left outer ear with upper limb exercises. the participants in group c will receive placebo tvns with upper limb exercises.

Eligibility criteria:
inclusion criteria: 1. aged between 50 and 80; 2. have suffered from a single stroke at least 1 year; 3. had volitional control of the non-paretic arm and at least minimal antigravity movement in the paretic shoulder; 4. scored 7 or above in the abbreviated mental test. exclusion criteria: 1. have cardiac pacemaker or cochlear implant; 2. have other neurological diseases; 3. are taking medication that may affect measured outcomes; 4. have skin lesions, infection, or inflammation near selected position; 5. are participating in other drug/treatment programs.
sex steroids, obesity and lipids in adolescent females

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity; Hypercholesterolemia

Summary: to prospectively explore the relationships of endogenous sex steroid hormones and obesity and their interactions with lipoprotein cholesterol and apolipoprotein levels in nine and ten year old black and white adolescent girls for five years during puberty.

background: in 1987, there was growing evidence that androgens, particularly when elevated, had an unfavorable effect on lipo/apo levels, tending to lower hdl cholesterol (hdlc) and raise ldl cholesterol (ldlc). previous studies confirmed that although pre-pubertal boys and girls had similar lipo/apo levels, post-pubertal boys had a higher ratio of ldlc/hdlc than girls, in part because of their androgen levels. such lipo/apo levels had been associated with an increased risk of coronary heart disease. there was also evidence that obese girls tended to be hyperandrogenic and thus had unfavorable lipo/apo levels and a higher risk of coronary heart disease. this study sought to elucidate whether high androgen levels preceded or were a consequence of obesity. design narrative: the longitudinal study was ancillary to the national growth and health study (nghs), a multicenter study which investigated the occurrence of obesity in black and white adolescent girls, predictors of the transition to the obese state, the correlates of the transition, and the relationship of the transition to other coronary heart disease risk factors. as part of the nghs, participants from the cincinnati, ohio and washington, d.c. public and parochial schools received physical examinations with attention to pubertal staging and anthropometric measurements including weight, height, and skinfold thickness. along with nghs blood samples, additional blood was obtained in years 1, 3, and 5 for measurements of lipids, lipoprotein cholesterols, apolipoproteins a1, a2, and b, and sex steroid hormones including plasma total and free testosterone, dehydroepiandrosterone sulfate, estradiol, and testosterone estrogen binding globulin. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
predictors of caregiver adaptation to pervasive developmental disorders

Conditions: Autism; Asperger's Syndrome; Rett's Disorder

Summary: this study will explore predictors of how caregivers might adapt to children diagnosed with a pervasive developmental disorder (pdd), including autism, asperger s syndrome, childhood disintegrative disorder, rett s disorder or other not specified pdd. pdd presents particular challenges for caregivers because of the communication and socialization challenges of affected children and because of the uncertainty surrounding the cause, prognosis and recurrence risks. people 18 years of age or older who are the primary caregiver for a child diagnosed with a pdd may be eligible for this study. participants fill out a survey, either online or in hard copy, that includes information in the following categories: * how being a caregiver for a child with a pdd has impacted the caregiver. * how much control the caregiver feels that he or she or others have over certain aspects of their child s pdd. * what the caregiver thinks caused the child s pdd. * what coping techniques the caregiver uses in caring for a child with a pdd. * how uncertain the caregiver feels about his or her child s pdd. * what the caregiver feels about him- or herself as a caregiver of a child with a pdd. * general questions about the caregiver, his or her family and the child with a pdd.

this study aims to understand the predictors of adaptation among primary caregivers of children with a pervasive developmental disorder (pdd). pdd presents particular challenges for caregivers because of the communication and socialization challenges of affected children, as well as the uncertainty surrounding the cause, prognosis and recurrence risks. the literature suggests that these challenges may make the process of adapting to having a child with a pdd different than it is for other chronic conditions. this study of caregivers is based on lazarus and folkman s transactional model of stress and coping. a cross-sectional design will be used to investigate the relationships among causal attributions, control perceptions, coping and adaptation. caregivers will be recruited from support groups, listservs and magazines targeted to autism and other pdds. participants will be asked to complete either a web-based or paper survey. the main outcome measure is psychological adaptation to caregiving a child with pdd.

Eligibility criteria:
* inclusion criteria: must be 18 or older and the primary caregiver for a child with one of the five diagnosis categorized as a pervasive developmental disorder. exclusion criteria: may not be younger than 18 years of age.

Keywords: adaptation pervasive developmental disorder autism spectrum disorders pervasive developmental disorders caregiver adaptation